Although it is possible that the antitumor activity of METTL3/14 inhibition may differ in ortho-topic models, patient-derived xenograft tumors, or other preclinical neuroblastoma models, it is well recognized that all preclinical models have inherent limitations and are not consistently predictive of response in patients. Here, METTL3 is linked to neuroblastoma.